New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT07348653
Summary
This is the first study in people to test a new drug called MG2512 injection for advanced solid tumors that have stopped responding to standard treatments. Researchers will give the drug to about 116 adults to check its safety, how the body processes it, and look for early signs it might help control cancer. The main goals are to find the highest safe dose and see what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sichuan Cancer Hospital
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.